# Cara Care

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cara-care

- Industry: Healthcare IT
- Headquarters: Hamburg, Germany
- Website: www.cara.care/
- Total disclosed funding: $17M
- Latest round: Series A (Jun 13, 2022)
- Investors on record: 4

## About

Founded in 2016 and based in Hamburg, Germany, HiDoc Technologies GmbH, dba Cara Care, operates as a provider of an application that tracks diet, symptoms, and digestive data as well as offers personal coaches for nutritional therapy. Jesaja Brinkmann and Andre Sommer are the co-founders of the company. In February 2024, Mahana Therapeutics, Inc., a portfolio company of Lux Capital, KKCG, Gurnet Point Capital, JAZZ Venture Partners, and Luminous Ventures, acquired Cara Care from Dr. Schär AG, Johnson & Johnson Innovation, Asabys Partners, and Atlantic Labs.

The company offers Cara Care, which is a mobile app designed to support individuals with chronic gastrointestinal issues. The firm’s papp provides personalized care for conditions like irritable bowel syndrome (IBS), Inflammatory Bowel Disease (IBD), Gastroesophageal Reflux Disease (GERD), and dyspepsia. Care Care’s features include tools for tracking food, symptoms, and overall well-being. The company allows users to be benefit from round-the-clock support, personalized dietician interactions, and an approach that encompasses nutrition, behavioral exercises, and emotional support. The firm’s data-driven insights help users monitor progress and manage their conditions.

## Funding rounds

- Series A, Jun 13, 2022, $6.9M — Johnson & Johnson Innovation, Atlantic Labs, Asabys Partners, Dr. Schär AG
- Series A, Jun 18, 2019, $7.9M — Johnson & Johnson Innovation, Atlantic Labs, Asabys Partners
- Seed, Aug 28, 2017, $2M — Atlantic Labs

## Investors

- Atlantic Labs (https://capitalatlas.ai/funds/atlantic-labs) — Seed, Series A
- Johnson & Johnson Innovation (https://capitalatlas.ai/funds/johnson-johnson-innovation) — Series A
- Asabys Partners (https://capitalatlas.ai/funds/asabys-partners) — Series A
- Dr. Schär AG — Series A